LNAI · Lunai Bioworks Inc.
$2.12
-0.12 (-5.36%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$81.25M
Shares
36.27M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2011
Net Income
-$178.01M
-101.3%
FY2025
Diluted EPS
-$86.40
-18.7%
FY2025
Operating Cash Flow
-$7.87M
+28.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | |
| -$110.94K | — | — | -$126.62K | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $5275 | $5275 | $295.66K | $295.66K | — | — | |
| — | — | — | — | — | — | — | — | — | $37.49K | $37.49K | -$295.66K | -$295.66K | — | — | |
| — | $537.43K | $2.71M | $4.17M | $8.37M | $15.54M | $4.69M | $2.5M | $616.96K | $62.76K | $804.19K | $1.63M | — | — | — | |
| $9.6M | $17.88M | $24.56M | $15.32M | $14.33M | $7.74M | $7.12M | $8.27M | $3.64M | $1.56M | $1.23M | $1.64M | $1.64M | $75.77K | $38.68K | |
| — | $9902 | $8296 | $6175 | $15K | $15.89K | $14.72K | $15.15K | $3.04M | — | — | — | — | — | — | |
| $96.48K | $129.1K | $121.86K | $113.5K | $123.59K | $123.54K | $108.58K | $71.71K | $2.86M | $14.53K | $27.4K | $18.98K | $18.98K | — | — | |
| $133.5M | $188.97M | $81.64M | $38.56M | $116.08M | $23.4M | $11.92M | $10.99M | $8.17M | $2.4M | $2.16M | $2.13M | $2.13M | — | — | |
| -$133.53M | -$188.97M | -$81.64M | -$38.56M | -$116.08M | -$23.4M | -$11.92M | -$10.99M | -$8.17M | -$2.4M | -$2.12M | -$2.43M | -$2.43M | — | — | |
| -$133.43M | -$188.84M | -$81.52M | -$38.44M | -$115.96M | -$23.28M | -$11.82M | -$10.92M | -$5.31M | -$2.39M | -$2.09M | -$2.41M | -$2.41M | — | — | |
| $539.99K | $725.68K | $1.01M | — | $372.84K | $379.61K | $104.28K | $43 | — | — | $2364 | $84.55K | $84.55K | $497 | — | |
| $115.08K | — | — | — | $122.04K | $13.18K | $50.3K | $73.49K | — | — | — | — | — | — | — | |
| $5.19M | $10.96M | -$6.79M | -$1.13M | $2.65M | -$3.45M | $507.41K | -$7.03M | -$1.09M | $192.72K | -$77.1K | -$119.2K | -$119.2K | — | — | |
| -$41.16M | — | — | -$39.68M | -$113.43M | -$26.85M | -$11.42M | -$18.02M | -$9.26M | -$2.21M | -$2.2M | -$2.55M | -$2.55M | -$76.27K | -$38.68K | |
| — | $1474 | — | $34 | $34 | -$125.28K | — | -$111.72K | -$111.72K | -$64.88K | -$462.79K | -$177.54K | -$177.54K | — | $0 | |
| -$128.28M | -$178.01M | -$88.43M | -$39.68M | -$113.43M | -$26.72M | -$11.42M | -$18.02M | -$9.15M | -$2.14M | -$1.74M | -$2.37M | -$2.37M | -$76.27K | -$38.68K | |
| -$129.22M | -$167.02M | -$88.57M | -$39.68M | -$113.45M | -$26.69M | -$11.6M | -$18.12M | -$9.3M | -$2.35M | -$1.71M | -$2.06M | -$2.06M | — | — | |
| USD/shares | — | -$86.40 | -$72.80 | -$56.80 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$86.40 | -$72.80 | -$56.80 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 2.06M | 1.22M | 703.32K | — | 589.59K | 579.13K | 469.4K | 274.26K | 153.33K | 119.17K | 93.75K | 93.75K | 62.5K | 40.13K |
| shares | — | 2.06M | 1.22M | 703.32K | — | 589.59K | 579.13K | 469.4K | 274.26K | 153.33K | 119.17K | 93.75K | 93.75K | 62.5K | 40.13K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.12×
EV/EBIT
—
Peer median 26.45×
P/E (TTM)
—
Peer median 2.11×
Peer medians compare against the 298 similar-size Biotechnology companies (of 522 listed).